Table 3.
Authors, year | Sources | Main polyphenols | Individuals | Duration | Bioactivities | Improvements |
---|---|---|---|---|---|---|
(Faghihzadeh, Adibi et al. 2015) [15] | Resveratrol capsules | Resveratrol | 50 NAFLD patients | 12 weeks | ND | ALT↓, hepatic steatosis↓ |
(Costabile, Vitale et al. 2018) [21] | Red grape pomace | Anthocyanins, flavan-3-ol, procyanidins | 12 healthy men | 1 week | ND | Postprandial insulin incremental area↓, insulin secretion index↓, IS index↑ |
(Fang, Kim et al. 2018) [22] | Mango | Gallic acid, gallotannin, galloylglycosides, flavonoids |
12 lean and 9 obese participants | 6 weeks | Anti-inflammation: IL-8↓ and MCP-1 ↓. | In lean participants: systolic BP↓ In obese participants: HbA1c and PAI-1↓ |
(Dallas, Gerbi et al. 2014) [27] | Sinetrol-XPur | Catechin, naringin | 95 overweight subjects | 12 weeks | Antioxidation: MDA↓, SOD↑, GSH↑ Anti-inflammation: CRP↓, fibrinogen↓ |
Waist and hip circumference↓, abdominal fat↓, body weight↓ |
(Astell, Mathai et al. 2013) [28] | C. fimbriata extract | Gallic acid | 43 overweight and obese subjects | 12 weeks | ND | Waist circumference↓, WHR↓ palatability of the test meal↓, sodium intake↓, body weight↓, BMI↓, hip circumference↓, systolic BP↓, HR↓, TG↓, total fat and saturated fat intake↓ |
(Taubert, Roesen et al. 2007) [36] | Cocoa-containing foods | Ericatechin, procyanidin dimer, flavonols | 44 untreated upper-range prehypertension or stage 1 hypertension | 18 weeks | Antioxidation: fasting plasma levels of S-nitrosoglutathione↑ | Systolic BP↓, diastolic BP↓, hypertension prevalence↓ |
(Rangel-Huerta, Aguilera et al. 2015) [38] | Orange juice | Anthocyanins | 100 obese or overweight adults | 12 weeks | Antioxidation: 8-OHdG↓, GR↓, erythrocyte catalase↓, 8-isoPGF2α↓, SOD↑ |
Body mass index↓, waist circumference↓, leptin↓, systolic and diastolic BP↓ |
(Chai, Davis et al. 2018) [39] | Tart cherry juice | Gallic acid | 17 men and 20 women | 12 weeks | ND | Systolic BP↓, LDLC↓, TC↓ |
(Erlund, Koli et al. 2008) [41] | Berry | Quercetin, caffeic acid, vanillic acid, | 72 unmedicated subjects with cardiovascular risks | 8 weeks | ND | HDLC↑, systolic BP↓ |
(Samavat, Newman et al. 2016) [42] | Green tea | Catechins | 936 women | 12 months | ND | Circulating TC↓, LDLC↓ Non-HDLC↓. |
(Faghihzadeh, Adibi et al. 2014) [46] | Resveratrol capsules | Resveratrol | 50 NAFLD patients | 12 weeks | Anti-inflammation: IL-6↓, NF-κB activity↓, serum CK-18 ↓ |
Weight↓, body mass index↓, waist circumference↓, ALT↓, hepatic steatosis grade↓ |
(Chen, Zhao et al. 2015) [47] | Resveratrol capsules | Resveratrol | 60 NAFLD patients | 3 months | Anti-inflammation: NF-κB activity ↓, serum CK-18 ↓ | AST↓, glucose↓, LDLC↓, ALT↓, TC↓HOMA-IR↓TNF-α↓, CK-18 fragment↓, FGF21↓, adiponectin level↑ |
(Martinez-Maqueda, Zapatera et al. 2018) [65] | Dried grape pomace | Anthocyanins, flavan-3-ol | 50 participants with at least one phenotype of MetS | 6 weeks | ND | IR↓, fasting insulinemia↓, Is↑ |
(Tynkkynen, Mursu et al. 2012) [66] | Chocolate | Epicatechin | 45 nonsmoking volunteers | 3 weeks | Antioxidation: oxidation susceptibility of serum lipids↓ |
HDL↑ |
(Mursu, Voutilainen et al. 2005) [67] | Polyphenol-rich phloem | Catechins | 75 nonsmoking hypercholesterolemic men | 4 weeks | Antioxidation: Oxidation resistance of total serum lipids↑ | Lipid peroxidation↓ |
(Espinosa-Moncada, Marin-Echeverri et al. 2018) [68] | Vaccinium meridionale Swartz (agraz) | Anthocyanins | 40 women with MetS | 4 weeks | Antioxidation: serum antioxidant capacity↑, urinary 8-OHdG ↓ Anti-inflammation: Hs-CRP levels ↓ |
Serum antioxidant capacity↑, DNA oxidative damage↓ |
(Vetrani, Vitale et al. 2018) [69] | ND | Flavonoids, flavan-3-ols, phenolic acids, flavonols | 78 individuals with at least one features of the MetS | 8 weeks | Antioxidation: urinary isoprostanes↓ |
Postprandial lipid response↓, VLDL↓, early insulin secretion↑ |
(Chiva-Blanch, Urpi-Sarda et al. 2013) [70] | Red wine | Catechin, epicatechin, malvidin-3-glucoside, gallic acid |
73 male moderate alcohol consumers | 4 weeks | ND | Plasma insulin↓, HOMA-IR↓, HDLC↑, Apo A-I↑, Apo A-II↑, lipoprotein↓ |
(↓): decrease; (↑): increase; ND: not detected. MetS: metabolic syndrome; IR: insulin resistance; IS: insulin sensitivity; IL: interleukin; MCP-1: monocyte chemotactic protein-1; HbA1c: glycosylated hemoglobin; PAI-1: plasminogen activator inhibitor 1; BP: blood pressure; MDA: malondialdehyde; SOD: superoxide dismutase; GSH: glutathione; CRP: C-reactive protein; WHR: waist to hip ratio; BMI: body mass index; HR: heart rate; TG: triacylglycerol; LDLC: low-density lipoprotein cholesterol; 8-OHdG: 8-hydroxydeoxyguanosine; GR: glutathione reductase; HDLC: high-density lipoprotein cholesterol; TC: total cholesterol; VLDL: very low-density lipoprotein; NAFLD: nonalcoholic fatty liver disease; ALT: alanine aminotransferase; NF-κB: nuclear factor-kappa B; CK: cytokeratin; FGF: fibroblast growth factor; 8-isoPGF2α: 8-iso-prostaglandin F2α; AST: aspartate aminotransferase; HOMA-IR: homeostasis model assessment insulin resistance index; TNF-α: tumor necrosis factor-alpha; hs-CRP: high-sensitivity C-reactive protein; Apo: apolipoprotein.